Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
296.6 USD | -1.19% | -4.32% | +2.78% |
May. 28 | US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment | RE |
May. 28 | Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.78% | 161B | |
+38.83% | 727B | |
+30.57% | 592B | |
-8.07% | 347B | |
+15.30% | 319B | |
-0.71% | 274B | |
+12.55% | 238B | |
+6.65% | 204B | |
-6.09% | 203B | |
-3.42% | 160B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Xeris Biopharma Shares Rise on Licensing Agreement With Amgen